Barclays Maintains an 'Overweight' on Celgene (CELG); Stumble in Europe, But Expect Continued U.S. Growth

June 22, 2012 2:56 PM EDT
Get Alerts CELG Hot Sheet
Price: $112.66 -0.84%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CELG Now!
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Celgene (NASDAQ: CELG) price target of $74.00 (from $83.00).

Analyst, Ying Huang, said, "Withdrawal of European application is disappointing, yet not completely unexpected...We lower our PT to $74, but stock should be supported by floor valuation of $60. Even without front-line maintenance approval in Europe, Revlimid should continue to grow in both the US and Europe on longer duration and higher number of patients."

Barclays lowers FY13 EPS estimate from $5.27 to $4.86.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $59.45 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities


Add Your Comment